🔥🔥#ESMO26 Top Thoracic Abstracts:
#DeLLphi305:
Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO in ES-SCLC
Definitely practice changing if we are able to deliver to more pts in the community , moving tarlatamab 1L maintenance
▶️Median OS: 21.1 vs 12.7 months (HR 0.42) 🔥
▶️12-month OS: 79.4% vs 53.3%
▶️Median PFS: 7.4 vs 1.9 months (HR 0.34)
▶️ORR: 26.4% vs 4.1%
⚠️ Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (mostly low grade).
#lcsm
@SclcSMASHERS
2 views · 0 likes · 0 reposts · 1 reply
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Dr. Estela Rodriguez@Latinamd
@SclcSMASHERS @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @glopesmd @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @NaglaAKarimMD @Annechiangmd @IASLC @larvol @oncbrothers @chinmay @Jani_Chinmay @colazagasti @myesmo
Source: Dr. Estela Rodriguez · x.com